

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

CUTC60

RRID:CVCL_VM61

Type: Cell Line

Proper Citation

RRID:CVCL_VM61

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_VM61

Proper Citation: RRID:CVCL_VM61

Description: Cell line CUTC60 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Thyroid gland anaplastic carcinoma

Defining Citation: [PMID:30733375](#), [PMID:30737244](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CUTC60

Cross References: cancercellines:CVCL_VM61, Wikidata:Q93460551

ID: CVCL_VM61

Record Creation Time: 20220427T215527+0000

Record Last Update: 20260815T232135+0000

Ratings and Alerts

No rating or validation information has been found for CUTC60.

No alerts have been found for CUTC60.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kellett MD, et al. (2025) Focal adhesion kinase promotes ribosome biogenesis to drive advanced thyroid cancer cell growth and survival. *Frontiers in oncology*, 15, 1252544.

Hicks HM, et al. (2024) The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. *Cancer biology & therapy*, 25(1), 2332000.

Hicks HM, et al. (2023) Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. *Molecular cancer research : MCR*, 21(9), 867.

Bolf EL, et al. (2023) Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity. *Cells*, 12(10).